Review



rabbit antihuman foxm1 polyclonal antibody  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Novus Biologicals rabbit antihuman foxm1 polyclonal antibody
    Figure 7. <t>FOXM1</t> contributes to EndMT and can be suppressed by sFRP3. A, Mitral VECs were treated with sham, post-MI plasma, and post-MI plasma with Siomycin A (1 µmol/L) for 24 hours before immunofluorescence staining using FOXM1 antibody (green; scale bar: 20 µm). B, Percentage of the cells positive for nuclear FOXM1 per total nuclei from 4 independent immunofluorescence assays were graphed. Statistical analysis was conducted using 1-way ANOVA with Tukey’s multiple comparisons test. C, Mitral VECs were treated with MI plasma (n=6) with and without Siomycin A (1 µmol/L) for 24 hours before qPCR analysis. Mean±SD from 3 independent assays were graphed. P values were calculated using the Wilcoxon signed-rank test and were significant (P<0.05) for all tested genes. D, Mitral VECs were treated with MI plasma (n=6) supplemented with sFRP3 (250 ng/mL) for 24 hours before qPCR analysis. Mean±SD from 3 independent assays were graphed. P value was calculated using nonparametric Mann- Whitney test. E, FOXM1 staining in mitral VECs following exposure to post-MI plasma and post-MI plasma supplemented with 250 ng/mL of sFRP3 for 24 hours. DAPI was used to stain nuclei (scale bar: 50 µm). F, Mean±SD of % cells positive for nuclear FOXM1 per total nuclei from 5 independent immunofluorescence assays with 2 individual post-MI plasma were graphed. P values were calculated using Mann-Whitney test. EndMT indicates endothelial-to-mesenchymal transition; FC, fold changes; FOXM1, forkhead box M1; MI, myocardial infarction; NS, not significant; qPCR, quantitative polymerase chain reaction; sFRP3, secreted frizzled-related protein 3; SioA, Siomycin A; and VEC, valve endothelial cell.
    Rabbit Antihuman Foxm1 Polyclonal Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit antihuman foxm1 polyclonal antibody/product/Novus Biologicals
    Average 92 stars, based on 4 article reviews
    rabbit antihuman foxm1 polyclonal antibody - by Bioz Stars, 2026-02
    92/100 stars

    Images

    1) Product Images from "Wnt Site Signaling Inhibitor Secreted Frizzled‐Related Protein 3 Protects Mitral Valve Endothelium From Myocardial Infarction–Induced Endothelial‐to‐Mesenchymal Transition"

    Article Title: Wnt Site Signaling Inhibitor Secreted Frizzled‐Related Protein 3 Protects Mitral Valve Endothelium From Myocardial Infarction–Induced Endothelial‐to‐Mesenchymal Transition

    Journal: Journal of the American Heart Association

    doi: 10.1161/jaha.121.023695

    Figure 7. FOXM1 contributes to EndMT and can be suppressed by sFRP3. A, Mitral VECs were treated with sham, post-MI plasma, and post-MI plasma with Siomycin A (1 µmol/L) for 24 hours before immunofluorescence staining using FOXM1 antibody (green; scale bar: 20 µm). B, Percentage of the cells positive for nuclear FOXM1 per total nuclei from 4 independent immunofluorescence assays were graphed. Statistical analysis was conducted using 1-way ANOVA with Tukey’s multiple comparisons test. C, Mitral VECs were treated with MI plasma (n=6) with and without Siomycin A (1 µmol/L) for 24 hours before qPCR analysis. Mean±SD from 3 independent assays were graphed. P values were calculated using the Wilcoxon signed-rank test and were significant (P<0.05) for all tested genes. D, Mitral VECs were treated with MI plasma (n=6) supplemented with sFRP3 (250 ng/mL) for 24 hours before qPCR analysis. Mean±SD from 3 independent assays were graphed. P value was calculated using nonparametric Mann- Whitney test. E, FOXM1 staining in mitral VECs following exposure to post-MI plasma and post-MI plasma supplemented with 250 ng/mL of sFRP3 for 24 hours. DAPI was used to stain nuclei (scale bar: 50 µm). F, Mean±SD of % cells positive for nuclear FOXM1 per total nuclei from 5 independent immunofluorescence assays with 2 individual post-MI plasma were graphed. P values were calculated using Mann-Whitney test. EndMT indicates endothelial-to-mesenchymal transition; FC, fold changes; FOXM1, forkhead box M1; MI, myocardial infarction; NS, not significant; qPCR, quantitative polymerase chain reaction; sFRP3, secreted frizzled-related protein 3; SioA, Siomycin A; and VEC, valve endothelial cell.
    Figure Legend Snippet: Figure 7. FOXM1 contributes to EndMT and can be suppressed by sFRP3. A, Mitral VECs were treated with sham, post-MI plasma, and post-MI plasma with Siomycin A (1 µmol/L) for 24 hours before immunofluorescence staining using FOXM1 antibody (green; scale bar: 20 µm). B, Percentage of the cells positive for nuclear FOXM1 per total nuclei from 4 independent immunofluorescence assays were graphed. Statistical analysis was conducted using 1-way ANOVA with Tukey’s multiple comparisons test. C, Mitral VECs were treated with MI plasma (n=6) with and without Siomycin A (1 µmol/L) for 24 hours before qPCR analysis. Mean±SD from 3 independent assays were graphed. P values were calculated using the Wilcoxon signed-rank test and were significant (P<0.05) for all tested genes. D, Mitral VECs were treated with MI plasma (n=6) supplemented with sFRP3 (250 ng/mL) for 24 hours before qPCR analysis. Mean±SD from 3 independent assays were graphed. P value was calculated using nonparametric Mann- Whitney test. E, FOXM1 staining in mitral VECs following exposure to post-MI plasma and post-MI plasma supplemented with 250 ng/mL of sFRP3 for 24 hours. DAPI was used to stain nuclei (scale bar: 50 µm). F, Mean±SD of % cells positive for nuclear FOXM1 per total nuclei from 5 independent immunofluorescence assays with 2 individual post-MI plasma were graphed. P values were calculated using Mann-Whitney test. EndMT indicates endothelial-to-mesenchymal transition; FC, fold changes; FOXM1, forkhead box M1; MI, myocardial infarction; NS, not significant; qPCR, quantitative polymerase chain reaction; sFRP3, secreted frizzled-related protein 3; SioA, Siomycin A; and VEC, valve endothelial cell.

    Techniques Used: Clinical Proteomics, Immunofluorescence, Staining, MANN-WHITNEY, Real-time Polymerase Chain Reaction

    Figure 8. Proposed model of EndMT induction in MV by post-MI plasma. sFRP3-deficient post-MI plasma releases the brake on Wnt signaling, increases FOXM1 transcriptional activity, nuclear localization of Slug, which initiates EndMT within days after MI. EndMT indicates endothelial-to-mesenchymal transition; FOXM1, forkhead box M1; MI, myocardial infarction; MV, mitral valve; NS, not significant; sFRP3, secreted frizzled-related protein 3; TGFβ, transforming growth factor beta; VE, vascular endothelial; and Wnt, wingless-related integration site.
    Figure Legend Snippet: Figure 8. Proposed model of EndMT induction in MV by post-MI plasma. sFRP3-deficient post-MI plasma releases the brake on Wnt signaling, increases FOXM1 transcriptional activity, nuclear localization of Slug, which initiates EndMT within days after MI. EndMT indicates endothelial-to-mesenchymal transition; FOXM1, forkhead box M1; MI, myocardial infarction; MV, mitral valve; NS, not significant; sFRP3, secreted frizzled-related protein 3; TGFβ, transforming growth factor beta; VE, vascular endothelial; and Wnt, wingless-related integration site.

    Techniques Used: Clinical Proteomics, Activity Assay



    Similar Products

    rabbit antihuman foxm1 polyclonal antibody  (Novus Biologicals)
    92
    Novus Biologicals rabbit antihuman foxm1 polyclonal antibody
    Figure 7. <t>FOXM1</t> contributes to EndMT and can be suppressed by sFRP3. A, Mitral VECs were treated with sham, post-MI plasma, and post-MI plasma with Siomycin A (1 µmol/L) for 24 hours before immunofluorescence staining using FOXM1 antibody (green; scale bar: 20 µm). B, Percentage of the cells positive for nuclear FOXM1 per total nuclei from 4 independent immunofluorescence assays were graphed. Statistical analysis was conducted using 1-way ANOVA with Tukey’s multiple comparisons test. C, Mitral VECs were treated with MI plasma (n=6) with and without Siomycin A (1 µmol/L) for 24 hours before qPCR analysis. Mean±SD from 3 independent assays were graphed. P values were calculated using the Wilcoxon signed-rank test and were significant (P<0.05) for all tested genes. D, Mitral VECs were treated with MI plasma (n=6) supplemented with sFRP3 (250 ng/mL) for 24 hours before qPCR analysis. Mean±SD from 3 independent assays were graphed. P value was calculated using nonparametric Mann- Whitney test. E, FOXM1 staining in mitral VECs following exposure to post-MI plasma and post-MI plasma supplemented with 250 ng/mL of sFRP3 for 24 hours. DAPI was used to stain nuclei (scale bar: 50 µm). F, Mean±SD of % cells positive for nuclear FOXM1 per total nuclei from 5 independent immunofluorescence assays with 2 individual post-MI plasma were graphed. P values were calculated using Mann-Whitney test. EndMT indicates endothelial-to-mesenchymal transition; FC, fold changes; FOXM1, forkhead box M1; MI, myocardial infarction; NS, not significant; qPCR, quantitative polymerase chain reaction; sFRP3, secreted frizzled-related protein 3; SioA, Siomycin A; and VEC, valve endothelial cell.
    Rabbit Antihuman Foxm1 Polyclonal Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit antihuman foxm1 polyclonal antibody/product/Novus Biologicals
    Average 92 stars, based on 1 article reviews
    rabbit antihuman foxm1 polyclonal antibody - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 7. FOXM1 contributes to EndMT and can be suppressed by sFRP3. A, Mitral VECs were treated with sham, post-MI plasma, and post-MI plasma with Siomycin A (1 µmol/L) for 24 hours before immunofluorescence staining using FOXM1 antibody (green; scale bar: 20 µm). B, Percentage of the cells positive for nuclear FOXM1 per total nuclei from 4 independent immunofluorescence assays were graphed. Statistical analysis was conducted using 1-way ANOVA with Tukey’s multiple comparisons test. C, Mitral VECs were treated with MI plasma (n=6) with and without Siomycin A (1 µmol/L) for 24 hours before qPCR analysis. Mean±SD from 3 independent assays were graphed. P values were calculated using the Wilcoxon signed-rank test and were significant (P<0.05) for all tested genes. D, Mitral VECs were treated with MI plasma (n=6) supplemented with sFRP3 (250 ng/mL) for 24 hours before qPCR analysis. Mean±SD from 3 independent assays were graphed. P value was calculated using nonparametric Mann- Whitney test. E, FOXM1 staining in mitral VECs following exposure to post-MI plasma and post-MI plasma supplemented with 250 ng/mL of sFRP3 for 24 hours. DAPI was used to stain nuclei (scale bar: 50 µm). F, Mean±SD of % cells positive for nuclear FOXM1 per total nuclei from 5 independent immunofluorescence assays with 2 individual post-MI plasma were graphed. P values were calculated using Mann-Whitney test. EndMT indicates endothelial-to-mesenchymal transition; FC, fold changes; FOXM1, forkhead box M1; MI, myocardial infarction; NS, not significant; qPCR, quantitative polymerase chain reaction; sFRP3, secreted frizzled-related protein 3; SioA, Siomycin A; and VEC, valve endothelial cell.

    Journal: Journal of the American Heart Association

    Article Title: Wnt Site Signaling Inhibitor Secreted Frizzled‐Related Protein 3 Protects Mitral Valve Endothelium From Myocardial Infarction–Induced Endothelial‐to‐Mesenchymal Transition

    doi: 10.1161/jaha.121.023695

    Figure Lengend Snippet: Figure 7. FOXM1 contributes to EndMT and can be suppressed by sFRP3. A, Mitral VECs were treated with sham, post-MI plasma, and post-MI plasma with Siomycin A (1 µmol/L) for 24 hours before immunofluorescence staining using FOXM1 antibody (green; scale bar: 20 µm). B, Percentage of the cells positive for nuclear FOXM1 per total nuclei from 4 independent immunofluorescence assays were graphed. Statistical analysis was conducted using 1-way ANOVA with Tukey’s multiple comparisons test. C, Mitral VECs were treated with MI plasma (n=6) with and without Siomycin A (1 µmol/L) for 24 hours before qPCR analysis. Mean±SD from 3 independent assays were graphed. P values were calculated using the Wilcoxon signed-rank test and were significant (P<0.05) for all tested genes. D, Mitral VECs were treated with MI plasma (n=6) supplemented with sFRP3 (250 ng/mL) for 24 hours before qPCR analysis. Mean±SD from 3 independent assays were graphed. P value was calculated using nonparametric Mann- Whitney test. E, FOXM1 staining in mitral VECs following exposure to post-MI plasma and post-MI plasma supplemented with 250 ng/mL of sFRP3 for 24 hours. DAPI was used to stain nuclei (scale bar: 50 µm). F, Mean±SD of % cells positive for nuclear FOXM1 per total nuclei from 5 independent immunofluorescence assays with 2 individual post-MI plasma were graphed. P values were calculated using Mann-Whitney test. EndMT indicates endothelial-to-mesenchymal transition; FC, fold changes; FOXM1, forkhead box M1; MI, myocardial infarction; NS, not significant; qPCR, quantitative polymerase chain reaction; sFRP3, secreted frizzled-related protein 3; SioA, Siomycin A; and VEC, valve endothelial cell.

    Article Snippet: Sections were then incubated with rabbit antihuman FOXM1 polyclonal antibody (Novus Biologicals, Littleton, CO; No. NBP1- 30961) diluted 1:300 or anti- Ki67 (Abcam; No. 15580) diluted 1:50 in 5% normal horse serum (Vector Laboratories, Burlingame, CA; No. S- 2000) for 90 minutes at room temperature, followed by 45 minutes incubation with antirabbit secondary antibody (LSAB Kit; Dako; No. K0675).

    Techniques: Clinical Proteomics, Immunofluorescence, Staining, MANN-WHITNEY, Real-time Polymerase Chain Reaction

    Figure 8. Proposed model of EndMT induction in MV by post-MI plasma. sFRP3-deficient post-MI plasma releases the brake on Wnt signaling, increases FOXM1 transcriptional activity, nuclear localization of Slug, which initiates EndMT within days after MI. EndMT indicates endothelial-to-mesenchymal transition; FOXM1, forkhead box M1; MI, myocardial infarction; MV, mitral valve; NS, not significant; sFRP3, secreted frizzled-related protein 3; TGFβ, transforming growth factor beta; VE, vascular endothelial; and Wnt, wingless-related integration site.

    Journal: Journal of the American Heart Association

    Article Title: Wnt Site Signaling Inhibitor Secreted Frizzled‐Related Protein 3 Protects Mitral Valve Endothelium From Myocardial Infarction–Induced Endothelial‐to‐Mesenchymal Transition

    doi: 10.1161/jaha.121.023695

    Figure Lengend Snippet: Figure 8. Proposed model of EndMT induction in MV by post-MI plasma. sFRP3-deficient post-MI plasma releases the brake on Wnt signaling, increases FOXM1 transcriptional activity, nuclear localization of Slug, which initiates EndMT within days after MI. EndMT indicates endothelial-to-mesenchymal transition; FOXM1, forkhead box M1; MI, myocardial infarction; MV, mitral valve; NS, not significant; sFRP3, secreted frizzled-related protein 3; TGFβ, transforming growth factor beta; VE, vascular endothelial; and Wnt, wingless-related integration site.

    Article Snippet: Sections were then incubated with rabbit antihuman FOXM1 polyclonal antibody (Novus Biologicals, Littleton, CO; No. NBP1- 30961) diluted 1:300 or anti- Ki67 (Abcam; No. 15580) diluted 1:50 in 5% normal horse serum (Vector Laboratories, Burlingame, CA; No. S- 2000) for 90 minutes at room temperature, followed by 45 minutes incubation with antirabbit secondary antibody (LSAB Kit; Dako; No. K0675).

    Techniques: Clinical Proteomics, Activity Assay